Florien W Boele1, Linda Douw2, Jaap C Reijneveld2, Rianne Robben2, Martin J B Taphoorn2, Neil K Aaronson2, Jan J Heimans2, Martin Klein2. 1. Florien W. Boele, Linda Douw, Jaap C. Reijneveld, Rianne Robben, Jan J. Heimans, and Martin Klein, VU University Medical Center; Neil K. Aaronson, Netherlands Cancer Institute, Amsterdam; and Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, the Netherlands. f.boele@vumc.nl. 2. Florien W. Boele, Linda Douw, Jaap C. Reijneveld, Rianne Robben, Jan J. Heimans, and Martin Klein, VU University Medical Center; Neil K. Aaronson, Netherlands Cancer Institute, Amsterdam; and Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, the Netherlands.
Abstract
PURPOSE: Patients with low-grade glioma (LGG) often experience long periods of stable disease, emphasizing the importance of maintaining good health-related quality of life (HRQOL). We assessed the changes in HRQOL in long-term survivors of WHO grade I or II astrocytoma, oligodendroglioma, or oligoastrocytoma with clinically and radiologically stable disease. PATIENTS AND METHODS: Patients completed self-report measures of generic HRQOL (Short Form-36 [SF-36]) and disease-specific HRQOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Cancer Module). Assessments took place at midterm and long-term follow-up, on average 6 and 12 years after histologic diagnosis and initial treatment, respectively. Comparisons between patients with LGG and individually matched healthy controls were made, and change within the patients with LGG was calculated, as was minimal detectable change. RESULTS: Although no statistically significant differences between patients with LGG and healthy matched controls were found at midterm follow-up, patients with LGG had worse physical role functioning (P = .004) and general health perceptions (P = .004) than controls at long-term follow-up. Within patients with stable LGG (n = 65), physical HRQOL (the SF-36 physical component summary and the physical functioning subscale) was significantly worse at long-term than at midterm follow-up (both P < .001). Although 48% of patients improved or remained stable on all HRQOL scales, 38.5% of patients experienced detectable decline on one or more scales. CONCLUSION: Although HRQOL remains mostly preserved in the majority of patients with LGG, a subset of patients experience detectable decline on one or more HRQOL scales despite long-term stable disease. For this subgroup, further research is recommended to better aid patients in dealing with the consequences of LGG.
PURPOSE:Patients with low-grade glioma (LGG) often experience long periods of stable disease, emphasizing the importance of maintaining good health-related quality of life (HRQOL). We assessed the changes in HRQOL in long-term survivors of WHO grade I or II astrocytoma, oligodendroglioma, or oligoastrocytoma with clinically and radiologically stable disease. PATIENTS AND METHODS: Patients completed self-report measures of generic HRQOL (Short Form-36 [SF-36]) and disease-specific HRQOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Brain Cancer Module). Assessments took place at midterm and long-term follow-up, on average 6 and 12 years after histologic diagnosis and initial treatment, respectively. Comparisons between patients with LGG and individually matched healthy controls were made, and change within the patients with LGG was calculated, as was minimal detectable change. RESULTS: Although no statistically significant differences between patients with LGG and healthy matched controls were found at midterm follow-up, patients with LGG had worse physical role functioning (P = .004) and general health perceptions (P = .004) than controls at long-term follow-up. Within patients with stable LGG (n = 65), physical HRQOL (the SF-36 physical component summary and the physical functioning subscale) was significantly worse at long-term than at midterm follow-up (both P < .001). Although 48% of patients improved or remained stable on all HRQOL scales, 38.5% of patients experienced detectable decline on one or more scales. CONCLUSION: Although HRQOL remains mostly preserved in the majority of patients with LGG, a subset of patients experience detectable decline on one or more HRQOL scales despite long-term stable disease. For this subgroup, further research is recommended to better aid patients in dealing with the consequences of LGG.
Authors: Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota Journal: Neuro Oncol Date: 2016-03 Impact factor: 12.300
Authors: Kristin Marie Knudsen-Baas; Tom Børge Johannesen; Tor Åge Myklebust; Jan Harald Aarseth; Jone Furlund Owe; Nils Erik Gilhus; Anette Margrethe Storstein Journal: J Neurooncol Date: 2018-11-23 Impact factor: 4.130
Authors: David Schiff; Martin Van den Bent; Michael A Vogelbaum; Wolfgang Wick; C Ryan Miller; Martin Taphoorn; Whitney Pope; Paul D Brown; Michael Platten; Rakesh Jalali; Terri Armstrong; Patrick Y Wen Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Ashlee R Loughan; Morgan Reid; Kelcie D Willis; Alexandria Davies; Rachel L Boutté; Sarah Barrett; Karen Lo Journal: J Neurooncol Date: 2022-04-08 Impact factor: 4.130
Authors: Emmanuel Mandonnet; Michel Wager; Fabien Almairac; Marie-Helene Baron; Marie Blonski; Christian F Freyschlag; Fabio Barone; Denys Fontaine; Johan Pallud; Monika Hegi; Catarina Viegas; Maria Zetterling; Giannantonio Spena; John Goodden; Geert-Jan Rutten; Luc Taillandier; Nicolas Foroglu; Amélie Darlix; Miran Skrap; Juan Martino; Gord von Campe; Caterina Madadaki; Etienne Gayat; Philip de Witt Hamer; Santiago Gil Robles; Silvio Sarubbo; Thomas Santarius; Lorenzo Bello; Marie-Therese Forster; Hugues Duffau Journal: Neurooncol Pract Date: 2017-01-17